This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: High clinical cure rate and evidence of rapid response in CAP

Clinical cure rates: FOCUS 1 and 2

FOCUS 1 and 2 trials: Two Phase III, randomised, double-blind, multinational, multicentre, non-inferiority trials comparing Zinforo (600 mg IV every 12 hours, adjusted for moderate renal impairment) vs ceftriaxone (1 g IV every 24 hours)2

Zinforo has proven efficacy in CAP patients…

Clinical cure rates: FOCUS 1 and 2||

… and high early clinical response rates at Day 4, including for Streptococcus pneumoniae infections.3‡

Zinforo delivers high cure rates in patients with severe disease, risk factors for difficult-to-treat infections and a number of comorbidities2

ZINFORO cure rates

Explore More

Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice.

 Access CAP patient profiles 

To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.

View CAPTURE study data 

||The lower limit of the 95% CI was above –10%, which met the predefined criteria for non-inferiority.7 Zinforo was well tolerated with a safety profile similar to that of ceftriaxone.7 
Zinforo may be associated with early clinical response, based on clinical stability and symptom improvement criteria. Early clinical response does not predict final clinical outcome for Zinforo.
*CrCL 31–50 mL/min.2 
Shown not to be statistically significant.3
§ Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.2
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1


CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CE, clinically evaluable; FOCUS, CeFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalised patients; MITTE, modified intent-to-treat efficacy; PORT, Pneumonia Patient Outcomes Research Team. NS, non significant 

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

  1. ZINFORO. Summary of Product Characteristics
  2. File TM, et al. Clin Infect Dis 2010;51:1395–405
  3. Eckburg P, et al. Infect Dis Clin Pract 2012;51:1395–405
  4. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  5. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  6. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
  7. Korczowski B et al, Paediatr Inf Dis J 2016 35 e239-47
PP-ZFO-GBR-0224. September 2021

Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials

View tolerability profile 

** This is an optional area where footnotes can live.

Explore the outcomes of the other Zinforo Phase III clinical trials in patients with CAP and cSSTI

Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1,4-6​​​​​​​

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?